Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.890
+0.060 (3.28%)
At close: Feb 19, 2026, 4:00 PM EST
1.871
-0.019 (-1.00%)
After-hours: Feb 19, 2026, 4:12 PM EST

Gain Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
7357493765-
Market Cap Growth
26.88%16.03%32.75%-42.34%--
Enterprise Value
6246381325-
Last Close Price
1.832.163.273.135.43-
PS Ratio
--894.85280.42481.65-
PB Ratio
11.147.813.931.971.85-
P/TBV Ratio
12.157.953.991.991.86-
EV/Sales Ratio
--691.9996.63186.53-
Debt / Equity Ratio
0.100.090.080.070.050.20
Net Debt / Equity Ratio
-1.39-1.33-1.25-1.10-1.01-1.00
Net Debt / EBITDA Ratio
0.470.480.711.172.551.80
Net Debt / FCF Ratio
0.470.520.841.412.831.91
Asset Turnover
--0.000.000.01-
Quick Ratio
2.302.853.444.9314.533.58
Current Ratio
2.522.973.595.1114.784.25
Return on Equity (ROE)
-261.72%-204.95%-141.57%-65.52%-67.73%-124.39%
Return on Assets (ROA)
-86.79%-82.80%-65.14%-35.24%-35.60%-42.37%
Return on Capital Employed (ROCE)
-258.70%-247.90%-162.90%-89.10%-38.00%-46.50%
Earnings Yield
-27.55%-35.63%-45.10%-47.29%-21.53%-
FCF Yield
-24.58%-32.98%-38.24%-39.82%-19.32%-
Buyback Yield / Dilution
-54.44%-75.86%-9.49%-16.90%-279.11%-19.17%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q